Celldex offers a catalyst-rich, well-funded bet on barzolvolimab becoming a disease-modifying mast cell therapy that could redefine chronic urticaria treatment.
Overview
Celldex is a high-conviction clinical-stage immunology biotech centered on barzolvolimab, a mast cell-depleting antibody with potentially best-in-disease efficacy in chronic urticarias. Phase 2 CSU data show deep complete responses, angioedema control and unusually durable off-treatment benefit, suggesting possible disease modification. A $345 million April 2026 financing lifted cash and securities to about $775 million, funding operations through 2028 and beyond the key Q4 2026 Phase 3 CSU readout and planned 2027 BLA filing.